1. Home
  2. KRNY vs LYEL Comparison

KRNY vs LYEL Comparison

Compare KRNY & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kearny Financial Corp

KRNY

Kearny Financial Corp

HOLD

Current Price

$7.89

Market Cap

504.9M

Sector

Finance

ML Signal

HOLD

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$23.64

Market Cap

490.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRNY
LYEL
Founded
1884
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
504.9M
490.1M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
KRNY
LYEL
Price
$7.89
$23.64
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
$8.00
$30.60
AVG Volume (30 Days)
278.9K
74.3K
Earning Date
04-23-2026
05-12-2026
Dividend Yield
5.55%
N/A
EPS Growth
130.22
N/A
EPS
0.30
N/A
Revenue
$2,580,000.00
$36,000.00
Revenue This Year
$3.89
N/A
Revenue Next Year
$17.52
$16,285.34
P/E Ratio
$26.38
N/A
Revenue Growth
36.00
N/A
52 Week Low
$5.76
$0.39
52 Week High
$8.50
$45.00

Technical Indicators

Market Signals
Indicator
KRNY
LYEL
Relative Strength Index (RSI) 58.53 54.62
Support Level $7.77 $21.27
Resistance Level $7.95 $27.30
Average True Range (ATR) 0.14 1.71
MACD 0.04 0.42
Stochastic Oscillator 68.98 73.24

Price Performance

Historical Comparison
KRNY
LYEL

About KRNY Kearny Financial Corp

Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.

Share on Social Networks: